Company Reports / Kyorin Pharmaceutical Co., LTD
COMPANY: Kyorin Pharmaceutical Co., LTD
INDEX RANK: 18th
Total Impact Score: 6,647.45
Kyorin Pharmaceutical Co., LTD is ranked 18th place in our index for 2015. Kyorin Pharmaceutical Co., LTD’s drugs have a total impact score of 6,647.45. Kyorin Pharmaceutical Co. Ltd. treats one disease in our model - XDR-TB - with one drug - Gatifloxacin (Gfx). Kyorin Pharmaceutical Co., Ltd. receives credit for one treatment against XDR-TB - Gatifloxacin (Gfx). This one drug averted 6,647.45 of the total DALYS for XDR-TB, which is 9.37% of the worldwide DALYs that we estimate would have been lost due to XDR-TB in 2015 in the absence of effective treatment. Kyorin Pharmaceutical Co., Ltd.’s drug portfolio placed it in a tie for 5th in terms of total averted DALYs for XDR-TB.
Company Score Breakdown:
Gatifloxacin (Gfx) is a quinolone antibiotic recommended by the WHO as a Group A second-line agent for treatment of multidrug-resistant tuberculosis. Gfx had a good safety profile and is effective against TB. However, due to adverse side effects including hepatotoxicity, Gatifloxacin was withdrawn in 2006, and is currently only available as an ophthalmic solution in the United States and Canada. Gfx was first patented by Kyorin Pharmaceuticals in 1986.
Kyorin Pharmaceutical Co., Ltd is a global pharmaceutical company founded in 1923 and headquartered in Tokyo, Japan. It is engaged in the manufacture and sale of prescription medicines, focusing on respiratory, urinary, ear, nose, and throat drugs. With a mission of looking to alleviate medical burden by providing innovative drugs globally, they seek to use their products to help better global health. Some of its key products include Mucodyne® and Kipres®. Kyorin originated and currently licenses gatifloxacin, a fluoroquinolone antibiotic, to various pharmaceutical companies. Its parent company, Kyorin Holdings Inc., reported revenue of $985.6 million in 2017. Kyorin Pharmaceutical Co., Ltd. employs approximately 1,670 people.